A smaller dose of Pfizer and BioNTech's Covid-19 vaccine is safe and generates a "robust" immune response in a clinical trial of kids ages 5 to 11, the drugmakers announced Monday. The news couldn't come any sooner for parents anxious to get their children vaccinated as kids start the new school year with the delta variant surging across America. Children's Covid cases remain disturbingly high with 243,000 new infections during the week ended Sept. 9. Pfizer CEO Albert Bourla said last week the company could submit data on children ages 5 to 11 by the end of this month. They said the shots were well tolerated and produced an immune response and side effects comparable to those seen in a study of people ages 16 to 25.
